Table 1.
AML- and AML/LSC-associated peptides.
| HLA class I–presented antigens | |||||||
|---|---|---|---|---|---|---|---|
| Memory T-cell responses | In vitro T-cell priming | ||||||
| ARP2A*01 | DIDTRSEFY | ARP2 | A*01 | 0/13 (0%) | 0/12 (0%) | 2/2 (100%) | n.a. |
| MYNNA*01 | FSEYFGAIY | MYNN | A*01 | 0/11 (0%) | 0/12 (0%) | 2/2 (100%) | TNF+ IFNγ+ CD107a+ |
| CEBPA A*01 | YLDGRLEPLY | CEBPA | A*01 | 0/11 (0%) | 0/12 (0%) | 2/2 (100%) | TNF+ IFNγ+ |
| CCNA1A*02 | SLLEADPFL | CCNA1 | A*02 | 0/16 (0%) | 0/14 (0%) | 4/4 (100%) | TNF+ IFNγ+ CD107a+ |
| DOCK8A*02 | IILDALPQL | DOCK8 | A*02 | 0/15 (0%) | 0/14 (0%) | 4/4 (100%) | TNF+ IFNγ+ CD107a+ |
| RUSF1A*02 | ILNDVAMFL | RUSF1 | A*02 | 0/14 (0%) | 0/15 (0%) | 4/4 (100%) | TNF+ IFNγ+ CD107a+ |
| STT3BB*07 | APESKHKSSL | STT3B | B*07 | 1/11 (9%) | 0/15 (0%) | 2/3 (66%) | n.a. |
| IRF7B*07 | APGLHLEL | IRF7 | B*07 | 0/12 (0%) | 0/16 (0%) | 5/5 (100%) | TNF+ IFNγ+ CD107a+ |
| OST48B*07 | APTIVGKSSL | OST48 | B*07 | 0/10 (0%) | 0/12 (0%) | 0/7 (0%) | — |
| ABCF2B*08 | DLDTRVAL | ABCF2 | B*08 | 0/11 (0%) | 0/13 (0%) | 2/3 (66%) | n.a. |
| TLE1B*08 | APTPRIKAEL | TLE1 | B*08/B*07 | 0/11 (0%) | 0/13 (0%) | 3/3 (100%) | n.a. |
| SF3A3B*08 | EGYGRYLDL | SF3A3 | B*08/B*14 | 0/11 (0%) | 0/11 (0%) | 1/1 (100%) | TNF+ IFNγ+ CD107a+ |
| UBE3BC*07 | SRPPLLGF | UBE3B | C*07 | 1/15 (7%) | 0/14 (0%) | n.a. | n.a. |
| CSN3C*07 | AYHELAQVY | CSN3 | C*07 | 0/15 (0%) | 0/14 (0%) | n.a. | — |
| RALYC*07 | IYSGYIFDY | RALY | C*07 | 1/15 (7%) | 1/13 (8%) | n.a. | TNF+ IFNγ+ |
| NPMmut_A*11 | AVEEVSLRK | NPMmut type A | A*11 | 1/13 (8%) | 0/9 (0%) | 3/3 (100%) | TNF+ IFNγ+ CD107a+ |
| NPMmut_A*03 | LAVEEVSLR | NPMmut type A | A*03 | 3/10 (30%) | 0/9 (0%) | n.a. | n.a. |
| UTR5_ CHRFAM7AA*02 | ILLSPPLLTI | UTR5 CHRFAM7A | A*02 | 0/12 (0%) | 0/23 (0%) | 1/1 (100%) | TNF+ IFNγ+ |
| Off-frame_TSPAN2B*07 | GPDDGRGVL | Off-frame TSPAN2 | B*07 | 0/7 (0%) | 0/23 (0%) | 2/2 (100%) | TNF+ IFNγ+ CD107a+ |
| HLA class II–presented antigens | |||||||
|---|---|---|---|---|---|---|---|
| Memory T-cell response | |||||||
| Peptide ID | Target class | Peptide sequence | Source protein | AML | HVs | Functionality of peptide-specific CD4+ T cells | |
| GALT7II | Peptide target | GNQLFRINEANQLMQ | GALT7 | 4/35 (11%) | 3/15 (20%) | TNF+ IFNγ+ CD107a+ | |
| CLC11II | Peptide target | DRQQMEALTRYLRAAL | CLC11 | 1/37 (3%) | 1/15 (7%) | n.a. | |
| APOBII | Peptide target | LGQEVALNANTKNQKIR | APOB | 1/37 (3%) | 1/15 (7%) | TNF+ IFNγ+ | |
| IL1APII_1 | Peptide target | NGRTFHLTRTLTVK | IL1AP | 3/33 (9%) | 5/15 (33%) | TNF+ IFNγ+ | |
| CCL23II | Protein target | SKPGVIFLTKKGRRF | CCL23 | 0/34 (0%) | 5/20 (25%) | TNF+ IFNγ+ | |
| FLT3II | Hotspot target | SPGPFPFIQDNISFYA | FLT3 | 5/33 (15%) | 1/14 (7%) | TNF+ IFNγ+ | |
| IL1APII_2 | Hotspot target | LDTMRQIQVFEDEPAR | IL1AP | 2/34 (6%) | 0/14 (0%) | TNF+ IFNγ+ | |
| HPRTII | Hotspot target | VVGYALDYNEYFRDL | HPRT | 4/31 (13%) | 1/14 (7%) | TNF+ IFNγ+ | |
| KITII | Hotspot target | IGSYIERDVTPAIM | KIT | 0/32 (0%) | 0/14 (0%) | — | |
| LTV1II | LSC-exclusive peptide target | PHRKKKPFIEKKKAVSFHLVHR | LTV1 | 0/31 (0%) | 2/14 (14%) | TNF+ IFNγ+ | |
| PPGBII | LSC-associated peptide target | KHLHYWFVESQKDPEN | PPGB | 1/31 (3%) | 0/14 (0%) | TNF+ IFNγ+ | |
| ITALII | LSC-associated peptide target | ETLHKFASKPASEFVK | ITAL | 2/31 (6%) | 0/14 (0%) | n.a. | |
| TACTII | LSC-associated protein target | DRVKLGTDYRLHLSPV | TACT (CD96) | 1/31 (3%) | 1/14 (7%) | TNF+ IFNγ+ | |
| G6PC3II | LSC-associated protein target | ERPEWIHVDSRPF | G6PC3 | 0/32 (0%) | 0/14 (0%) | — | |
| IDH2mut_II | Neoepitope | KLKKMWKSPNGTIQNILGGTVF | IDH2 R140Q | 0/31 (0%) | 6/25 (24%) | TNF+ IFNγ+ | |
NOTE: Immunogenicity analysis of AML- and AML/LSC-associated peptides. Preexisting memory T-cell responses in AML patient and HV samples were investigated by IFNγ ELISpot assays after peptide-specific 12-day in vitro expansion. In vitro T-cell priming of peptide-specific T cells was conducted using aAPCs. Functionality of peptide-specific T cells was analyzed by intracellular cytokine (IFNγ, TNF) and degranulation marker (CD107a) staining.
Abbreviations: ID, identification; n.a., not available.